Terumo to Acquire WuXi Biologics’ German Plant for €150M

• Terumo has agreed to acquire WuXi Biologics’ drug product plant in Leverkusen, Germany, for €150 million.

• The acquisition marks Terumo’s first overseas CDMO production site, aimed at expanding global biopharma manufacturing capacity.

Terumo Corporation has announced a €150 million agreement to acquire WuXi Biologics’ drug product (DP) manufacturing plant located in Leverkusen, Germany. The facility will serve as Terumo’s first overseas base for its contract development and manufacturing organisation (CDMO) business.

The site spans 13,000 square metres and employs approximately 150 people. It is equipped with GMP-compliant facilities and will support the production of prefilled syringe and vial products. Terumo plans to utilise the site’s capabilities to meet growing global demand for CDMO services, particularly in Europe and the United States.

The acquisition aligns with Terumo’s long-term strategy to globalise its CDMO operations. The company currently operates CDMO facilities in Japan at its Kofu, Fujinomiya, and Yamaguchi factories. In December 2023, it expanded capacity at Yamaguchi, and is building a new production line at Kofu, due for completion in fiscal 2025.

“The acquisition of the drug product plant is a pivotal step in enhancing the competitiveness of our CDMO business, and we are thrilled to have reached an agreement with WuXi Biologics,” said Hikaru Samejima, Chief Executive Officer, Terumo Corporation.

Terumo expects the integration of the Leverkusen site and its workforce to enhance the company’s responsiveness to pharmaceutical clients globally.